ECSP034867A - MÉTODOS PARA ADMINISTRAR ANTICUERPOS ANTI-TNFa - Google Patents

MÉTODOS PARA ADMINISTRAR ANTICUERPOS ANTI-TNFa

Info

Publication number
ECSP034867A
ECSP034867A EC2003004867A ECSP034867A ECSP034867A EC SP034867 A ECSP034867 A EC SP034867A EC 2003004867 A EC2003004867 A EC 2003004867A EC SP034867 A ECSP034867 A EC SP034867A EC SP034867 A ECSP034867 A EC SP034867A
Authority
EC
Ecuador
Prior art keywords
htnfa
antibodies
antibody
methods
less
Prior art date
Application number
EC2003004867A
Other languages
English (en)
Inventor
Joachim Kempeni
Steven A Fischkoff
Roberta Weiss
Original Assignee
Abbott Biotech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23144283&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP034867(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Biotech Ltd filed Critical Abbott Biotech Ltd
Publication of ECSP034867A publication Critical patent/ECSP034867A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/28—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)

Abstract

Métodos para tratar trastornos en los cuales tiene injerencia el TNFa, que comprenden la administración subcutánea, cada dos semanas, de anticuerpos humanos, preferiblemente anticuerpos recombinantes humanos, que se unen al factor de necrosis tumoral humano a (hTNFa). El anticuerpo puede administrarse con o sin metotrexato. Estos anticuerpos tienen una alta afinidad por hTNFa (por ejemplo, Kd = 10-8 M o menos), una baja velocidad de salida para la disociación con hTNFa (por ejemplo, Koff = 10-3 sec-1 o menos) y neutralizan la actividad de hTNFa in vitro e in vivo. Un anticuerpo de la invención puede ser un anticuerpo completo o una porción de unión a antígeno del mismo. También se incluyen conjuntos de elementos (kits) que contienen una composición farmacéutica e instrucciones para su dosificación, y jeringas cargadas que contienen composiciones farmacéuticas
EC2003004867A 2001-06-08 2003-11-27 MÉTODOS PARA ADMINISTRAR ANTICUERPOS ANTI-TNFa ECSP034867A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29696101P 2001-06-08 2001-06-08

Publications (1)

Publication Number Publication Date
ECSP034867A true ECSP034867A (es) 2004-01-28

Family

ID=23144283

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004867A ECSP034867A (es) 2001-06-08 2003-11-27 MÉTODOS PARA ADMINISTRAR ANTICUERPOS ANTI-TNFa

Country Status (32)

Country Link
US (16) US8889135B2 (es)
EP (6) EP2364731A3 (es)
JP (7) JP2005517629A (es)
KR (8) KR101497363B1 (es)
CN (5) CN103495165A (es)
AR (3) AR034429A1 (es)
AU (1) AU2002314922C1 (es)
BG (2) BG66459B1 (es)
BR (1) BR0206289A (es)
CA (3) CA2385745C (es)
CL (1) CL2012000856A1 (es)
CY (1) CY1120540T1 (es)
CZ (1) CZ309160B6 (es)
DK (2) DK2940044T3 (es)
EC (1) ECSP034867A (es)
ES (2) ES2612436T3 (es)
HU (1) HU230947B1 (es)
IL (4) IL158831A0 (es)
LT (1) LT2940044T (es)
MX (2) MXPA03011316A (es)
NO (2) NO334490B1 (es)
NZ (6) NZ529574A (es)
PE (2) PE20030065A1 (es)
PH (3) PH12013500297A1 (es)
PL (4) PL217217B1 (es)
PT (2) PT2940044T (es)
SA (1) SA02230384B1 (es)
SI (2) SI2940044T1 (es)
SK (1) SK288509B6 (es)
TW (1) TWI473622B (es)
WO (1) WO2002100330A2 (es)
ZA (1) ZA200308861B (es)

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
DE122004000004I1 (de) * 1996-02-09 2004-08-12 Abott Biotechnology Ltd Humane Antikörper welche an Humanen TNFalpha binden.
CA2385745C (en) 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20030206898A1 (en) * 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20040009172A1 (en) * 2002-04-26 2004-01-15 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
AR040603A1 (es) * 2002-07-19 2005-04-13 Abbott Lab S A El uso de un anticuerpo anti-tnfalfa neutralizador de alta afinidad en la fabricacion de un medicamento y conjunto de elementos
US20090280065A1 (en) * 2006-04-10 2009-11-12 Willian Mary K Uses and Compositions for Treatment of Psoriasis
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
WO2004087730A2 (en) * 2003-03-27 2004-10-14 The Johns Hopkins University Method for producing diverse libraries of encoded polymers
US8273347B2 (en) * 2003-05-13 2012-09-25 Depuy Spine, Inc. Autologous treatment of degenerated disc with cells
US7344716B2 (en) * 2003-05-13 2008-03-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
US7892563B2 (en) * 2003-05-20 2011-02-22 Wyeth Holdings Corporation Methods for treatment of severe acute respiratory syndrome (SARS)
US8361467B2 (en) * 2003-07-30 2013-01-29 Depuy Spine, Inc. Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints
US8895540B2 (en) * 2003-11-26 2014-11-25 DePuy Synthes Products, LLC Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
AU2011218744B2 (en) * 2004-04-09 2012-09-20 Abbvie Biotechnology Ltd Multiple-variable dose regimen for treating TNFalpha-related disorders
TWI439284B (zh) * 2004-04-09 2014-06-01 Abbvie Biotechnology Ltd 用於治療ＴＮＦα相關失調症之多重可變劑量療法
GB0414054D0 (en) 2004-06-23 2004-07-28 Owen Mumford Ltd Improvements relating to automatic injection devices
WO2006014477A1 (en) * 2004-07-06 2006-02-09 Bioren, Inc. HIGH AFFINITY ANTI-TNF-α ANTIBODIES AND METHOD
EP1807111A4 (en) * 2004-10-08 2009-05-27 Abbott Biotech Ltd SYNCYTIAL RESPIRATORY VIRUS INFECTION (RSV)
US20060253100A1 (en) 2004-10-22 2006-11-09 Medtronic, Inc. Systems and Methods to Treat Pain Locally
JP5129122B2 (ja) 2005-04-26 2013-01-23 トリオン ファーマ ゲーエムベーハー 癌治療のための抗体およびグルココルチコイドの組み合わせ
AU2012254978C1 (en) * 2005-05-16 2017-06-01 Abbvie Biotechnology Ltd Use of TNF inhibitor for treatment of erosive polyarthritis
AU2006246721B2 (en) 2005-05-16 2012-12-13 Abbvie Biotechnology Ltd Use of TNF inhibitor for treatment of erosive polyarthritis
US20070041905A1 (en) * 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
CA2626804A1 (en) 2005-11-01 2007-08-09 Abbott Biotechnology Ltd. Methods and compositions for diagnosing ankylosing spondylitis using biomarkers
WO2007110219A1 (en) * 2006-03-27 2007-10-04 Ablynx N.V. Medical delivery device for therapeutic proteins based on single domain antibodies
CA3086149A1 (en) 2006-04-04 2007-10-11 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
MX2008012896A (es) 2006-04-05 2008-10-14 Abbott Biotech Ltd Purificacion de anticuerpos.
WO2007120651A2 (en) * 2006-04-10 2007-10-25 Abbott Biotechnology Ltd. Uses and compositions for treatment of juvenile rheumatoid arthritis
WO2007120656A2 (en) * 2006-04-10 2007-10-25 Abbott Biotechnology Ltd. Uses and compositions for treatment of rheumatoid arthritis
EP2666472A3 (en) 2006-04-10 2014-04-02 Abbott Biotechnology Ltd Uses and compositions for treatment of psoriatic arthritis
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US20090317399A1 (en) * 2006-04-10 2009-12-24 Pollack Paul F Uses and compositions for treatment of CROHN'S disease
EP2708242A3 (en) 2006-04-10 2014-03-26 Abbott Biotechnology Ltd Uses and compositions for treatment of ankylosing spondylitis
CA2564435A1 (en) 2006-04-10 2007-10-10 Abbott Biotechnology Ltd. Methods for monitoring and treating intestinal disorders
WO2007120626A2 (en) 2006-04-10 2007-10-25 Abbott Biotechnology Ltd. Uses and compositions for treatment of ankylosing spondylitis
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
CN101426514A (zh) * 2006-04-25 2009-05-06 英特塞尔股份公司 Hcv疫苗
US20080311043A1 (en) * 2006-06-08 2008-12-18 Hoffman Rebecca S Uses and compositions for treatment of psoriatic arthritis
US20100021451A1 (en) 2006-06-08 2010-01-28 Wong Robert L Uses and compositions for treatment of ankylosing spondylitis
CN103316402A (zh) 2006-06-30 2013-09-25 艾伯维生物技术有限公司 自动注射装置
NZ576133A (en) 2006-10-27 2012-10-26 Abbott Biotech Ltd Crystalline anti-htnfalpha antibodies
WO2008150491A2 (en) * 2007-05-31 2008-12-11 Abbott Laboratories BIOMARKERS PREDICTIVE OF THE RESPONSIVENESS TO TNFα INHIBITORS IN AUTOIMMUNE DISORDERS
WO2008154543A2 (en) 2007-06-11 2008-12-18 Abbott Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis
EP2173380A4 (en) * 2007-07-13 2011-08-31 Abbott Biotech Ltd METHOD AND COMPOSITIONS FOR PULMONARY ADMINISTRATION OF A TNFa HEMMER
WO2009020654A1 (en) 2007-08-08 2009-02-12 Abbott Laboratories Compositions and methods for crystallizing antibodies
NZ622583A (en) 2007-11-30 2015-08-28 Abbvie Biotechnology Ltd Protein formulations and methods of making same
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
US8986696B2 (en) 2007-12-21 2015-03-24 Depuy Mitek, Inc. Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints
PL2808343T3 (pl) 2007-12-26 2019-11-29 Xencor Inc Warianty Fc ze zmienionym wiązaniem do FcRn
CN101965514A (zh) * 2008-01-03 2011-02-02 艾博特生物技术有限公司 预测化合物在治疗银屑病中的长期功效
BRPI0907186A2 (pt) 2008-01-15 2015-07-14 Abbott Gmbh & Co Kg Composições proteicas pulverizadas e métodos para sua produção
US20100040630A1 (en) * 2008-03-24 2010-02-18 Aake Elden Methods and compositions for treating bone loss
USRE48948E1 (en) 2008-04-18 2022-03-01 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
US20100239632A1 (en) 2009-03-23 2010-09-23 Warsaw Orthopedic, Inc. Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
CA2758964A1 (en) 2009-04-16 2010-10-21 Abbott Biotherapeutics Corp. Anti-tnf-.alpha. antibodies and their uses
CN102458517B (zh) 2009-04-29 2014-07-23 阿布维生物技术有限公司 自动注射装置
NZ600069A (en) 2009-12-15 2015-02-27 Abbvie Biotechnology Ltd Improved firing button for automatic injection device
JP2013514388A (ja) 2009-12-16 2013-04-25 フィリップ ボッシュ， 間質性膀胱炎の処置の方法
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
EP2531613A2 (en) 2010-02-02 2012-12-12 Abbott Biotechnology Ltd. Methods and compositions for predicting responsiveness to treatment with tnf-alpha inhibitor
NZ702172A (en) 2010-04-21 2016-03-31 Abbvie Biotechnology Ltd Wearable automatic injection device for controlled delivery of therapeutic agents
US20110287018A1 (en) 2010-05-19 2011-11-24 Philip Bosch Methods of Treating Interstitial Cystitis
HUE039740T2 (hu) 2010-06-03 2019-01-28 Abbvie Biotechnology Ltd Alkalmazások és készítmények hidradenitis suppurativa (HS) kezelésére
AR083495A1 (es) 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
AU2011325974B2 (en) 2010-11-11 2016-10-27 Abbvie Biotechnology Ltd. Improved high concentration anti-TNFalpha antibody liquid formulations
EP3187216B1 (en) 2011-01-24 2019-08-21 AbbVie Biotechnology Ltd. Automatic injection devices having overmolded gripping surfaces
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US10040855B2 (en) * 2011-05-02 2018-08-07 Millennium Pharmaceuticals, Inc. Formulation for anti-α4β7 antibody
KR102103036B1 (ko) 2011-06-13 2020-04-22 압제노믹스 코오페라티에프 유.에이. 항-ｐｓｇｌ-１ 항체 및 그의 용도
US8795357B2 (en) 2011-07-15 2014-08-05 Edwards Lifesciences Corporation Perivalvular sealing for transcatheter heart valve
HK1202628A1 (en) 2011-11-30 2015-10-02 Abbvie Deutschland Gmbh & Co Kg Methods and compositions for determining responsiveness to treatment with a tnf-alpha inhibitor
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9505833B2 (en) 2012-04-20 2016-11-29 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
HK1211981A1 (en) 2012-09-02 2016-06-03 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
AU2013312300A1 (en) 2012-09-07 2015-04-16 Coherus Biosciences, Inc. Stable aqueous formulations of adalimumab
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
WO2015057910A1 (en) 2013-10-16 2015-04-23 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
US9763992B2 (en) 2014-02-13 2017-09-19 Father Flanagan's Boys' Home Treatment of noise induced hearing loss
GB201407852D0 (en) * 2014-05-02 2014-06-18 Iontas Ltd Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules
CA2949236C (en) 2014-05-15 2023-06-13 Incube Labs, Llc Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
US10689460B2 (en) 2014-05-15 2020-06-23 Incube Labs, Llc PCSK9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US11548940B2 (en) 2014-05-15 2023-01-10 Rani Therapeutics, Llc Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
EP3145951A1 (en) 2014-06-24 2017-03-29 InSight Biopharmaceuticals Ltd. Methods of purifying antibodies
AU2015298263B2 (en) 2014-07-31 2020-05-14 Anji Pharmaceuticals, Inc. ApoE mimetic peptides and higher potency to clear plasma cholesterol
CN104382977A (zh) * 2014-11-17 2015-03-04 昆明朗盛生物科技有限公司 一种女性专用的玛咖组合物
EP3237000A1 (en) 2014-12-23 2017-11-01 Pfizer Inc Stable aqueous antibody formulation for anti tnf alpha antibodies
US10696735B2 (en) 2015-01-21 2020-06-30 Outlook Therapeutics, Inc. Modulation of charge variants in a monoclonal antibody composition
EP3078675A1 (en) 2015-04-10 2016-10-12 Ares Trading S.A. Induction dosing regimen for the treatment of tnf alpha mediated disorders
AU2016257813B2 (en) 2015-05-01 2021-05-13 Rani Therapeutics, Llc Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
US10988543B2 (en) 2015-11-11 2021-04-27 Opi Vi—Ip Holdco Llc Humanized anti-tumor necrosis factor alpha receptor 2 (anti-TNFR2) antibodies and methods of use thereof to elicit an immune response against a tumor
EP3411401A1 (en) 2016-02-03 2018-12-12 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
TWI819435B (zh) * 2016-03-07 2023-10-21 法商賽諾菲生物技術公司 用於治療類風濕性關節炎之組成物及方法
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
SG10202001787QA (en) 2016-06-02 2020-04-29 Abbvie Inc Glucocorticoid receptor agonist and immunoconjugates thereof
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
KR20190024572A (ko) * 2017-08-30 2019-03-08 (주)셀트리온 TNFα 관련 질환을 치료하기 위한 피하 투여 요법
EP3456739A1 (en) * 2017-09-19 2019-03-20 Tillotts Pharma Ag Use of anti-tnfalpha antibodies for treating wounds
CA3082356A1 (en) 2017-12-01 2019-06-06 Abbvie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof
CN112955222A (zh) 2018-08-29 2021-06-11 里珍纳龙药品有限公司 用于治疗患有类风湿性关节炎的个体的方法和组合物
TW202521583A (zh) 2019-01-31 2025-06-01 法商賽諾菲生物技術公司 用於治療幼年原發性關節炎之組成物及方法
AR118191A1 (es) * 2019-02-28 2021-09-22 Celltrion Inc MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON TNFa
JP2022525332A (ja) * 2019-03-14 2022-05-12 ビオンド バイオロジクス リミテッド 免疫抑制の方法
MA55760A (fr) 2019-04-24 2022-03-02 Regeneron Pharma Procédés de diagnostic et de traitement de la polyarthrite rhumatoïde
JP2022534794A (ja) 2019-06-04 2022-08-03 サノフィ・バイオテクノロジー 関節リウマチを有する対象における疼痛を治療するための組成物および方法
TWI841810B (zh) * 2020-01-24 2024-05-11 日商西斯美股份有限公司 提升抗體對抗原之親和性的方法及其用途
US20230091156A1 (en) * 2021-09-14 2023-03-23 Mayo Foundation For Medical Education And Research Methods and materials for assessing and treating arthritis
TW202509220A (zh) * 2023-06-26 2025-03-01 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 經工程化之瘧原蟲及相關方法
KR20250031013A (ko) * 2023-08-23 2025-03-06 (주)셀트리온 TNFα 관련 질환을 치료하는 방법

Family Cites Families (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
CA1208546A (en) 1981-09-08 1986-07-29 Anthony Cerami Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
IL73883A (en) 1984-12-20 1990-12-23 Yeda Res & Dev Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
EP0613006A1 (en) 1985-08-16 1994-08-31 The Rockefeller University Antibodies to cachectin and immunoassays
US4870163A (en) 1985-08-29 1989-09-26 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
US5246714A (en) 1985-10-11 1993-09-21 Aktiebolaget Hassle Drug preparation
GB8528234D0 (en) 1985-11-15 1985-12-18 Wyeth John & Brother Ltd Heterocyclic compounds
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
EP0230574A3 (en) 1986-01-31 1989-03-22 Yale University Pharmaceutical compositions against infections caused by lav/htlv iii virus and the use thereof
DE3631229A1 (de) 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
JP2638652B2 (ja) 1988-07-18 1997-08-06 カイロン・コーポレーション カケクチンと反応するモノクロナール抗体
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE68914244T2 (de) 1988-10-24 1994-10-27 Otsuka Pharma Co Ltd Monoklonaler Antikörper.
EP0374510B1 (en) 1988-12-19 1997-01-15 American Cyanamid Company Products for the treatment of endotoxic shock in a mammal
JP3443119B2 (ja) 1989-08-07 2003-09-02 ペプテック リミテッド 腫瘍壊死因子結合リガンド
FR2651130B1 (fr) 1989-08-23 1991-12-13 Roussel Uclaf Sequence d'oligonucleotides anti-sens, anti-arn message du tnf alpha, procede de preparation, application a titre de medicaments et compositions pharmaceutiques.
GB8921123D0 (en) 1989-09-19 1989-11-08 Millar Ann B Treatment of ards
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5945098A (en) 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
DE4037604A1 (de) 1990-04-25 1991-10-31 Bayer Ag Verwendung von anti-tnf-antikoerpern als arzneimittel bei der behandlung von ischaemien und deren folgen
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
JPH06508511A (ja) 1990-07-10 1994-09-29 ケンブリッジ　アンティボディー　テクノロジー　リミティド 特異的な結合ペアーの構成員の製造方法
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2090401A1 (en) 1990-08-27 1992-02-28 Deborah A. Rathjen Method of treating viral infection
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5994510A (en) 1990-12-21 1999-11-30 Celltech Therapeutics Limited Recombinant antibodies specific for TNFα
GB9109645D0 (en) 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
GB2279077B (en) 1990-12-21 1995-06-14 Celltech Ltd Therapeutic compositions comprising recombinant antibodies specific for the TNFalpha
GB9028123D0 (en) 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
DE69233769D1 (de) 1991-03-01 2009-09-24 Dyax Corp Chimäres Protein mit Mikroprotein mit zwei oder mehr Disulfidbindungen und Ausgestaltungen davon
DE69233069T2 (de) 1991-03-15 2003-11-27 Amgen Inc., Thousand Oaks Pegylation von polypeptiden
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US20060246073A1 (en) 1991-03-18 2006-11-02 Knight David M Anti-TNF antibodies and peptides of human tumor necrosis factor
US20040120952A1 (en) 2000-08-07 2004-06-24 Centocor, Inc Anti-TNF antibodies and peptides of human tumor necrosis factor
US5698195A (en) 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
EP1097945B1 (en) 1991-03-18 2007-07-04 New York University Monoclonal and chimeric antibody specific for human tumor necrosis factor
US20070298040A1 (en) 1991-03-18 2007-12-27 Centocor, Inc. Methods of treating seronegative arthropathy with anti-TNF antibodies
ATE171471T1 (de) 1991-03-29 1998-10-15 Immunex Corp Isolierte virale proteine als cytokinantagonisten
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
EP0940468A1 (en) * 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
ATE181571T1 (de) 1991-09-23 1999-07-15 Medical Res Council Methoden zur herstellung humanisierter antikörper
AU3244693A (en) 1991-12-17 1993-07-19 Schering Corporation Use of the combination of anti-tumor necrosis factor plus interleukin-6 to treat septic shock
US5195967A (en) * 1992-02-18 1993-03-23 Nakao Naomi L Anticlotting device and method for use with IV catheters
US5605923A (en) 1992-04-02 1997-02-25 Smithkline Beecham Corporation Compounds useful for treating inflammatory diseases and inhibiting production of tumor necrosis factor
EP0585705B1 (en) 1992-08-28 1998-11-04 Bayer Corporation Use of monoclonal antibodies to TNF to treat bacterial meningitis
JPH07504203A (ja) 1992-09-15 1995-05-11 イミュネックス・コーポレーション 腫瘍壊死因子アンタゴニストを用いるｔｎｆ−依存性炎症の治療方法
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
WO1994008609A1 (en) 1992-10-15 1994-04-28 Dana-Farber Cancer Institute, Inc. TREATMENT OF INSULIN RESISTANCE IN OBESITY LINKED TYPE II DIABETES USING ANTAGONISTS TO TNF-α FUNCTION
DE69427928T3 (de) 1993-03-05 2012-05-10 Bayer Healthcare Llc Humane monoklonale anti-TNF alpha Antikörper
DE4307508A1 (de) 1993-03-10 1994-09-15 Knoll Ag Verwendung von anti-TNF-Antikörpern als Arzneimittel bei der Behandlung von Herzinsuffizienz (Herzmuskelschwäche)
ATE183513T1 (de) 1993-06-03 1999-09-15 Therapeutic Antibodies Inc Herstellung von antikörperfragmenten
US5500227A (en) 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
EP0659766A1 (en) 1993-11-23 1995-06-28 Schering-Plough Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
NZ278607A (en) 1994-02-07 1999-05-28 Knoll Ag Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above
WO1995023813A1 (en) 1994-03-04 1995-09-08 Merck & Co., Inc. In vitro antibody affinity maturation using alanine scanning mutagenesis
ZA955642B (en) 1994-07-07 1997-05-06 Ortho Pharma Corp Lyophilized imaging agent formulation
PT1516628E (pt) 1995-07-27 2013-09-24 Genentech Inc Formulação de proteína liofilizada isotónica estável
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
DE122004000004I1 (de) * 1996-02-09 2004-08-12 Abott Biotechnology Ltd Humane Antikörper welche an Humanen TNFalpha binden.
GB9610992D0 (en) * 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
JP2000516594A (ja) 1996-07-26 2000-12-12 スミスクライン・ビーチャム・コーポレイション 免疫細胞介在全身性疾患の改良された治療法
DK0999853T3 (da) 1997-06-13 2003-04-22 Genentech Inc Stabiliseret antostofformulering
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US5971953A (en) * 1998-01-09 1999-10-26 Bachynsky; Nicholas Dual chamber syringe apparatus
TR200103054T2 (tr) 1998-06-15 2002-06-21 Sepracor Inc. Apne,bulimi ve başka bozuklukların tedavi edilmesi için optik açıdan saf (+)-norsisapridin kullanımı
JP3889197B2 (ja) * 1999-02-22 2007-03-07 中外製薬株式会社 プランジャロッド付きシリンジ製剤の製造方法及びその組付装置
US6419944B2 (en) 1999-02-24 2002-07-16 Edward L. Tobinick Cytokine antagonists for the treatment of localized disorders
US6537549B2 (en) 1999-02-24 2003-03-25 Edward L. Tobinick Cytokine antagonists for the treatment of localized disorders
US6015557A (en) 1999-02-24 2000-01-18 Tobinick; Edward L. Tumor necrosis factor antagonists for the treatment of neurological disorders
US6423321B2 (en) 1999-02-24 2002-07-23 Edward L. Tobinick Cytokine antagonists for the treatment of sensorineural hearing loss
AU756677B2 (en) 1999-03-02 2003-01-23 Centocor Inc. Anti-TNFalpha antibodies in therapy of asthma
EP1041072B1 (en) 1999-03-31 2003-07-16 Pfizer Products Inc. Dioxocyclopentyl hydroxamic acids
SE9901366D0 (sv) * 1999-04-16 1999-04-16 Pharmacia & Upjohn Ab Injector device and method for its operation
CA2371427A1 (en) 1999-04-28 2000-11-09 Yamanouchi Pharmaceutical Co., Ltd. Parenteral pharmaceutical composition containing humanized monoclonal antibody fragment and stabilizing method thereof
US6502867B2 (en) 1999-06-16 2003-01-07 United States Pipe & Foundry Flanged pipe fitting
EP1189628A1 (en) 1999-06-24 2002-03-27 Pharmacia Corporation Combination of tumor necrosis factor (tnf) antagonists and cox-2 inhibitors for the treatment of inflammation
ATE389414T1 (de) * 1999-09-08 2008-04-15 Chugai Pharmaceutical Co Ltd Stabile proteinlösung abgefüllt in einem behältnis aus hydrophobem harz und eine methode zur stabilisierung derselben
AU3082401A (en) 1999-11-24 2001-06-04 Centocor Inc. Therapy of psoriasis
WO2001047554A1 (fr) 1999-12-28 2001-07-05 Chugai Seiyaku Kabushiki Kaisha Compositions d'anticorps stables et preparations pour injection
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
US20050249735A1 (en) 2000-08-07 2005-11-10 Centocor, Inc. Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor
US20060018907A1 (en) 2000-08-07 2006-01-26 Centocor, Inc. Anti-TNF antibodies and peptides of human tumor necrosis factor
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US20030012786A1 (en) 2001-05-25 2003-01-16 Teoh Leah S. Use of anti-TNF antibodies as drugs in treating septic disorders of anemic patients
CA2385745C (en) 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
PL217752B1 (pl) * 2001-08-23 2014-08-29 Genmab As Izolowane ludzkie przeciwciało monoklonalne wobec IL-15 lub jego fragment wiążący antygen i związane z nimi hybrydoma, kompozycja farmaceutyczna oraz zastosowania medyczne
US20030161828A1 (en) 2002-02-19 2003-08-28 Abbott Gmbh & Co. Kg Use of TNF antagonists as drugs for the treatment of patients with an inflammatory reaction and without suffering from total organ failure
CN1305905C (zh) 2002-03-22 2007-03-21 Aprogen株式会社 人源化抗体及其制备方法
US20040009172A1 (en) 2002-04-26 2004-01-15 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
AR040603A1 (es) 2002-07-19 2005-04-13 Abbott Lab S A El uso de un anticuerpo anti-tnfalfa neutralizador de alta afinidad en la fabricacion de un medicamento y conjunto de elementos
US20090280065A1 (en) 2006-04-10 2009-11-12 Willian Mary K Uses and Compositions for Treatment of Psoriasis
US7226426B2 (en) 2002-07-25 2007-06-05 Thomson Paul E Apparatus and method for the detection and quantification of joint and tissue inflammation
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
TWI439284B (zh) 2004-04-09 2014-06-01 Abbvie Biotechnology Ltd 用於治療ＴＮＦα相關失調症之多重可變劑量療法
EP1807111A4 (en) 2004-10-08 2009-05-27 Abbott Biotech Ltd SYNCYTIAL RESPIRATORY VIRUS INFECTION (RSV)
AU2006246721B2 (en) 2005-05-16 2012-12-13 Abbvie Biotechnology Ltd Use of TNF inhibitor for treatment of erosive polyarthritis
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
CA2626804A1 (en) 2005-11-01 2007-08-09 Abbott Biotechnology Ltd. Methods and compositions for diagnosing ankylosing spondylitis using biomarkers
MX2008012896A (es) 2006-04-05 2008-10-14 Abbott Biotech Ltd Purificacion de anticuerpos.
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
CN103316402A (zh) 2006-06-30 2013-09-25 艾伯维生物技术有限公司 自动注射装置
NZ576133A (en) 2006-10-27 2012-10-26 Abbott Biotech Ltd Crystalline anti-htnfalpha antibodies
WO2009020654A1 (en) 2007-08-08 2009-02-12 Abbott Laboratories Compositions and methods for crystallizing antibodies
WO2014152463A1 (en) 2013-03-15 2014-09-25 Cyberheart, Inc. Apparatus and method for real-time tracking of tissue structures
CN102458517B (zh) 2009-04-29 2014-07-23 阿布维生物技术有限公司 自动注射装置
RU2560701C2 (ru) 2009-05-04 2015-08-20 Эббви Байотекнолоджи Лтд. Стабильные композиции с высокими концентрациями белков антител человека против tnf-альфа
CN102167741B (zh) 2010-02-25 2014-05-14 上海百迈博制药有限公司 一种全人源抗TNF-α单克隆抗体、其制备方法及用途
HUE039740T2 (hu) 2010-06-03 2019-01-28 Abbvie Biotechnology Ltd Alkalmazások és készítmények hidradenitis suppurativa (HS) kezelésére
GB201112429D0 (en) 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
JP6274421B2 (ja) 2013-03-22 2018-02-07 キヤノンメディカルシステムズ株式会社 超音波診断装置及びその制御プログラム
KR102197477B1 (ko) 2014-07-04 2020-12-31 주식회사 유풍 모자

Also Published As

Publication number Publication date
EP1406656B1 (en) 2013-01-09
EP2940044B8 (en) 2017-01-18
NO20035426L (no) 2004-02-03
US20130004507A1 (en) 2013-01-03
HK1065471A1 (en) 2005-02-25
HUP0600688A3 (en) 2012-09-28
IL222495A (en) 2015-03-31
EP1406656A2 (en) 2004-04-14
EP2324851A1 (en) 2011-05-25
CN105412922A (zh) 2016-03-23
US20150071945A1 (en) 2015-03-12
MXPA03011316A (es) 2004-12-06
US20150175691A1 (en) 2015-06-25
KR101282807B1 (ko) 2013-07-05
BG111719A (bg) 2014-06-30
NZ560792A (en) 2009-09-25
PL394085A1 (pl) 2011-07-04
IL212419A (en) 2015-03-31
US8911737B2 (en) 2014-12-16
PH12013500866B1 (en) 2016-02-22
US20120177596A1 (en) 2012-07-12
EP2940044A1 (en) 2015-11-04
KR101715028B1 (ko) 2017-03-10
CA2385745C (en) 2015-02-17
US20150023982A1 (en) 2015-01-22
AR034429A1 (es) 2004-02-25
IL212419A0 (en) 2011-06-30
KR101142825B1 (ko) 2012-05-08
CA2385745A1 (en) 2002-12-08
CA2868614A1 (en) 2002-12-08
TWI473622B (zh) 2015-02-21
CA2817619A1 (en) 2002-12-08
BG108514A (en) 2005-04-30
ES2612436T3 (es) 2017-05-16
PL399491A1 (pl) 2012-10-08
US20150246968A1 (en) 2015-09-03
BG66936B1 (bg) 2019-08-15
NO334490B1 (no) 2014-03-17
EP2940044B1 (en) 2016-11-16
PL399548A1 (pl) 2012-11-05
TW201332570A (zh) 2013-08-16
PL217217B1 (pl) 2014-06-30
SA02230384B1 (ar) 2009-08-19
US9546212B2 (en) 2017-01-17
US20200181252A1 (en) 2020-06-11
US9073987B2 (en) 2015-07-07
PT2940044T (pt) 2017-01-12
KR20090035746A (ko) 2009-04-10
SK288509B6 (sk) 2017-11-03
AU2002314922B2 (en) 2008-05-15
SI2940044T1 (sl) 2017-03-31
PH12013500865B1 (en) 2018-06-27
US20140271637A1 (en) 2014-09-18
US20150017175A1 (en) 2015-01-15
PH12013500865A1 (en) 2016-02-01
PL217666B1 (pl) 2014-08-29
NO20035426D0 (no) 2003-12-05
US8992926B2 (en) 2015-03-31
EP2364731A9 (en) 2012-06-20
PL217702B1 (pl) 2014-08-29
KR101497363B1 (ko) 2015-03-03
PH12013500866A1 (en) 2016-02-22
US8889135B2 (en) 2014-11-18
BR0206289A (pt) 2004-11-30
EP2359855A2 (en) 2011-08-24
US20150079101A1 (en) 2015-03-19
SI1406656T1 (sl) 2013-04-30
AR090099A2 (es) 2014-10-22
NO20120288L (no) 2004-02-03
NZ596878A (en) 2013-07-26
CY1120540T1 (el) 2019-07-10
AR077572A2 (es) 2011-09-07
JP2012184242A (ja) 2012-09-27
JP2005517629A (ja) 2005-06-16
JP2009167193A (ja) 2009-07-30
CN101574520A (zh) 2009-11-11
NZ586063A (en) 2012-02-24
CN103110944A (zh) 2013-05-22
NZ529574A (en) 2006-05-26
MX341001B (es) 2016-08-03
LT2940044T (lt) 2017-01-10
KR20040030661A (ko) 2004-04-09
US20140186368A1 (en) 2014-07-03
BG66459B1 (bg) 2014-10-31
KR20080089681A (ko) 2008-10-07
PH12013500297A1 (en) 2015-09-07
ES2400458T3 (es) 2013-04-10
JP6302529B2 (ja) 2018-03-28
EP2364731A3 (en) 2011-11-02
EP2364731A2 (en) 2011-09-14
DK2940044T3 (en) 2017-02-20
JP5832952B2 (ja) 2015-12-16
KR20100075698A (ko) 2010-07-02
AU2002314922C1 (en) 2017-11-09
HU230947B1 (hu) 2019-05-28
CN103495165A (zh) 2014-01-08
WO2002100330A9 (en) 2007-06-21
EP3190124A1 (en) 2017-07-12
ZA200308861B (en) 2004-09-13
JP2015003922A (ja) 2015-01-08
EP2359855A9 (en) 2012-06-20
CN1638796A (zh) 2005-07-13
NO343721B1 (no) 2019-05-20
NZ545649A (en) 2009-04-30
US9017680B2 (en) 2015-04-28
KR20140012210A (ko) 2014-01-29
PT1406656E (pt) 2013-03-25
JP2013100311A (ja) 2013-05-23
PE20030065A1 (es) 2003-02-12
PE20160999A1 (es) 2016-10-08
US8974790B2 (en) 2015-03-10
IL158831A (en) 2014-06-30
US20150071939A1 (en) 2015-03-12
PL366694A1 (en) 2005-02-07
JP6074462B2 (ja) 2017-02-01
CL2012000856A1 (es) 2012-09-14
JP2015166389A (ja) 2015-09-24
EP2359855A3 (en) 2011-11-02
WO2002100330A2 (en) 2002-12-19
US20030235585A1 (en) 2003-12-25
HUP0600688A2 (en) 2006-11-28
CZ200420A3 (cs) 2005-01-12
CZ309160B6 (cs) 2022-03-30
US20140322232A1 (en) 2014-10-30
SK16462003A3 (sk) 2004-08-03
WO2002100330A3 (en) 2004-02-12
KR20120139851A (ko) 2012-12-27
KR20110039505A (ko) 2011-04-18
US20160280777A1 (en) 2016-09-29
DK1406656T3 (da) 2013-04-15
PL215861B1 (pl) 2014-02-28
JP2017031213A (ja) 2017-02-09
IL158831A0 (en) 2004-05-12
EP1406656A4 (en) 2006-05-24
NZ573478A (en) 2011-02-25
US20150165023A1 (en) 2015-06-18
KR20160096222A (ko) 2016-08-12

Similar Documents

Publication Publication Date Title
ECSP034867A (es) MÉTODOS PARA ADMINISTRAR ANTICUERPOS ANTI-TNFa
UY27780A1 (es) Uso de anticuerpos anti-tnf alfa y otro fármaco
EA201992590A1 (ru) Стабильные композиции антител к рецептору программируемой гибели 1 (pd-1) и способы их применения
PH12021550802A1 (en) Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof
PE20240913A1 (es) Anticuerpos anti-il-2r agonistas y metodos de uso
AR072897A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5
AR111497A1 (es) Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estos
EP1156823A4 (en) METHODS FOR TREATING TUMORS AND METASTASES USING AN ANTI-ANGIOGENIC AND IMMUNE THERAPIES
ECSP024210A (es) Moléculas de anticuerpo que tienen especificidad por el factor de necrosis tumoral alfa humano, y uso de las mismas
ATE465255T1 (de) Verabreichung von sirnas
PE20021151A1 (es) Uso de anticuerpos anti-tnf como farmacos en el tratamiento de trastornos septicos de racientes anemicos
DE60239454D1 (de) Rekombinanter, tumorspezifischer antikörper und dessen verwendung
EA202193240A1 (ru) Стабилизированные составы, содержащие анти-angptl3 антитела
UA116194C2 (uk) Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном
BRPI0516953A (pt) partìculas do tipo vìrus compreendendo uma proteìna de fusão da proteìna de revestimento de ap205 e um polipeptìdeo antigênico
ATE535252T1 (de) Peptid-konjugat-zusammensetzungen und -verfahren zur prävention und behandlung von alzheimer- krankheit
EA200702656A1 (ru) Составы, содержащие пептиды, стимулирующие рецептор эритропоэтина, и их применение
ATE490785T1 (de) Parathormon-antikörper und damit zusammenhängende verfahren
MX2025012892A (es) Anticuerpos que se unen a ox40l y metodos de uso
ATE418344T1 (de) Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten
Schmidinger et al. Sequential administration of interferon γ and interleukin-2 in metastatic renal cell carcinoma: results of a phase II trial
UY27323A1 (es) Métodos para administrar anticuerpos anti-tnfa
CY1113774T1 (el) ΜΕΘΟΔΟΙ ΧΟΡΗΓΗΣΗΣ ΑΝΤΙΣΩΜΑΤΩΝ ANTI-TNFa
BR112022003498A2 (pt) Peptídeos recombinantes do tipo elastina imunotolerantes e métodos de uso
EA202190176A1 (ru) Антигенсвязывающий белок, связывающий steap1